Stealth BioTherapeutics - MITO Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.32
+0 (0.00%)
Get New Stealth BioTherapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MITO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MITO

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Stealth BioTherapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.32.

This chart shows the closing price for MITO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Stealth BioTherapeutics. This rating has held steady since May 2023, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/22/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/18/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/16/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/15/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/14/2025

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
6/16/2022HC WainwrightReiterated RatingBuy$1.50
6/9/2022HC WainwrightReiterated RatingBuy$1.50
5/23/2022HC WainwrightLower TargetBuy$4.00 ➝ $1.50
3/17/2022HC WainwrightReiterated RatingBuy$4.00
2/16/2022HC WainwrightReiterated RatingBuy$4.00
1/12/2022HC WainwrightReiterated RatingBuy$4.00
7/1/2021Maxim GroupInitiated CoverageBuy$3.00
5/20/2021HC WainwrightReiterated RatingBuy
5/8/2020HC WainwrightReiterated RatingBuy$5.00 ➝ $4.00
4/14/2020Roth CapitalInitiated CoverageBuy$9.00
4/3/2020Nomura SecuritiesLower TargetBuy$14.00 ➝ $10.00
4/2/2020BMO Capital MarketsBoost TargetMarket Perform$3.00 ➝ $7.00
4/2/2020HC WainwrightUpgradeNeutral ➝ Buy$5.00
2/18/2020Cantor FitzgeraldReiterated RatingOverweight$7.00 ➝ $10.00
(Data available from 2/14/2020 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/19/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/18/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/17/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/17/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/16/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/16/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/15/2025
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/14/2025

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Stealth BioTherapeutics logo
Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate is Elamipretide that is in phase 3 clinical trial to treat barth syndrome, phase 2/3 clinical trial for the treatment of duchenne cardiomyopathy, phase 2a clinical trial to treat friedreich's ataxia, phase 2 clinical trial for the treatment of dry age-related macular degeneration, phase 2 clinical trial to treat leber's hereditary optic neuropathy, and phase 3 clinical trial for the treatment of replisome myopathies. The company's product candidates also include SBT-20 to treat complications of diabetes, renal diseases, ocular diseases, neurodegenerative, Parkinson's, Alzheimer's, Huntington's, and ALS diseases; SBT-550 for rare neurological indications; and SBT-272, a peptidomimetic that targets the mitochondria and stabilizing mitochondrial function under conditions of oxidative stress, as well as SBT 550. Stealth BioTherapeutics Corp was incorporated in 2006 and is based in George Town, the Cayman Islands.
Read More

Today's Range

Now: $0.32
Low: $0.32
High: $0.32

50 Day Range

MA: $0.32
Low: $0.31
High: $0.32

52 Week Range

Now: $0.32
Low: $0.16
High: $1.03

Volume

N/A

Average Volume

946,105 shs

Market Capitalization

$23.54 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.46

Frequently Asked Questions

What sell-side analysts currently cover shares of Stealth BioTherapeutics?

The following Wall Street sell-side analysts have issued stock ratings on Stealth BioTherapeutics in the last year:
View the latest analyst ratings for MITO.

What is the current price target for Stealth BioTherapeutics?

0 Wall Street analysts have set twelve-month price targets for Stealth BioTherapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Stealth BioTherapeutics in the next year.
View the latest price targets for MITO.

What is the current consensus analyst rating for Stealth BioTherapeutics?

Stealth BioTherapeutics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for MITO.

What other companies compete with Stealth BioTherapeutics?

How do I contact Stealth BioTherapeutics' investor relations team?

Stealth BioTherapeutics' physical mailing address is 275 GROVE STREET SUITE 3-107, NEWTON MA, 02466. The company's listed phone number is 617-600-6888 and its investor relations email address is [email protected]. The official website for Stealth BioTherapeutics is www.stealthbt.com. Learn More about contacing Stealth BioTherapeutics investor relations.